---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-025635"
form_type: "8-K"
ticker: "TERN"
cik: "0001831363"
company_name: "Terns Pharmaceuticals, Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:24:02.009652+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Terns Pharma appoints Andrew Gengos as CFO effective Feb 24, 2025

## Summary
- Andrew Gengos named CFO effective Feb 24; salary $510K, bonus target 40%, option for 750K shares vesting over 4 years.
- Most recently CFO/Chief Business Officer at Athira Pharma (May 2023-Oct 2024); previously CEO at ImmunoCellular and Neuraltus.
- CEO Amy Burroughs remains CEO but steps down as principal financial officer; David Strauss remains VP Finance and steps down as principal accounting officer.
- Stock option exercise price equals closing price on start date; 25% vests at one year, then monthly over three years.

## SEC filing metadata
- accession: 0000950170-25-025635
- form_type: 8-K
- ticker: TERN
- cik: 0001831363
- company_name: Terns Pharmaceuticals, Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831363/000095017025025635/0000950170-25-025635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831363/000095017025025635/tern-20250222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-025635
- JSON: https://secwatch.observer/filing/0000950170-25-025635.json
- Plain text: https://secwatch.observer/filing/0000950170-25-025635.txt

## Source-grounded claims
- claim_id: 64fce5cfde
  claim: Andrew Gengos was appointed as Chief Financial Officer at Terns Pharmaceuticals, Inc..
  evidence_excerpt: Mr. Gengos will serve as the Chief Financial Officer of Terns, effective as of February 24, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831363/000095017025025635/0000950170-25-025635-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.